Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on Monday, April 2, 2018
29. März 2018 08:30 ET
|
Dare Bioscience, Inc.
SAN DIEGO, March 29, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, announced that it has released financial results for the full...
Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive
12. März 2018 08:00 ET
|
Dare Bioscience, Inc.
Advancing 6- and 12- month injectable contraceptive development work carried out to date under a subcontract funded by Family Health International (FHI 360) through a grant from the Bill & Melinda...
Daré Bioscience, Inc. To Participate in the 30th Annual ROTH Conference
05. März 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson,...
Daré Bioscience, Inc. To Participate in the LD Micro Virtual Conference
27. Februar 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson, President and...
Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder
15. Februar 2018 11:06 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it has met the funding requirement for...
Daré Bioscience, Inc. to raise approximately $10.25 million
13. Februar 2018 09:18 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE) today announced the pricing of its previously announced underwritten public offering of 5.0 million shares of its...
Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock
12. Februar 2018 20:57 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it intends to offer primary shares of its...
Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder
12. Februar 2018 08:00 ET
|
Dare Bioscience, Inc.
Company enters into license agreement with Strategic Science & Technologies, LLC to develop Topical Sildenafil, now in Phase 2 clinical studies SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Daré...
Daré Bioscience, Inc. to Present at the 2018 BIO CEO & Investor Conference
06. Februar 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a healthcare company committed to the development and commercialization of innovative products in women’s...
Daré Bioscience, Inc. to Present at the LD Micro 10th Annual Main Event Conference
04. Dezember 2017 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a healthcare company committed to the development and commercialization of innovative products in women’s...